New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:04 EDTNKTRNektar announces dosing of first subject in Phase 1 study for NKTR-171
Nektar Therapeutics announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.
News For NKTR From The Last 14 Days
Check below for free stories on NKTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:59 EDTNKTRNektar reports Q2 EPS (26c), consensus (37c)
Subscribe for More Information
July 28, 2014
07:43 EDTNKTRNektar shares offer favorable risk/reward, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use